quartr
REC: H1 2026 revenue up 6.6% to €1.41B, EBITDA margin 38.3%, guidance reaffirmed
Net revenue rose 6.6% to €1.41 billion in H1 2026, driven by Rare Diseases growth and strong product performance. EBITDA margin improved to 38.3%, and adjusted net income increased 6.7%. Full-year guidance is confirmed, with continued investment in pipeline and strategic collaborations.Original doc…